ReviewJournal of gastroenterology and hepatology2008
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.
Review in Journal of gastroenterology and hepatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Pooled it
- Liver sinusoidal endothelial cell defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by a sodium-glucose cotransporter 2 inhibitor but not by an angiotensin-converting enzyme inhibitor.Cardiovascular research · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review.World journal of cardiology · 2026Review
- Effects of water-deprivation stress on the expression of hepatic genes involved in blood pressure and stress response in chickens.Frontiers in physiology · 2026Article
- Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno-Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2024Article
- Correlation between Exposure to UFP and ACE/ACE2 Pathway: Looking for Possible Involvement in COVID-19 Pandemic.Toxics · 2024Article
- The Renin-Angiotensin System in Liver Disease.International journal of molecular sciences · 2024Review
- [Hemodynamic Changes in Chronic Liver Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease.Journal of Korean medical science · 2023Article
- Vitamin D improves hepatic alterations inSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Altered local RAS in the liver increased the risk of NAFLD in male mouse offspring produced by in vitro fertilization.BMC pregnancy and childbirth · 2023Article
- Cirrhotic Cardiomyopathy Following Bile Duct Ligation in Rats-A Matter of Time?International journal of molecular sciences · 2023Article
- Effects of PM2.5 Exposure on the ACE/ACE2 Pathway: Possible Implication in COVID-19 Pandemic.International journal of environmental research and public health · 2023Article
- Severe acute respiratory syndrome coronavirus 2 may cause liver injuryWorld journal of virology · 2023Review
- Association of COVID-19 with hepatic metabolic dysfunction.World journal of virology · 2022Review
- Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.JCI insight · 2022Article
- Inhalation exposure to silver nanoparticles induces hepatic inflammation and oxidative stress, associated with altered renin-angiotensin system signaling, in Wistar rats.Environmental toxicology · 2022Article
- Effects of dipeptidyl peptidase-4 inhibition on portal hypertensive and cirrhotic rats.Journal of the Chinese Medical Association : JCMA · 2021Article
- Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care.Journal of clinical and translational hepatology · 2021Review
- Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renin-angiotensin system (RAS) is a key regulator of vascular resistance, sodium and water homeostasis and the response to tissue injury. Historically, angiotensin II (Ang II) was thought to be the primary effector peptide of this system. Ang II is produced predominantly by the effect of angiotensin converting enzyme (ACE) on angiotensin I (Ang I). Ang II acts mainly through the angiotensin II type-1 receptor (AT(1)) and, together with ACE, these components represent the 'classical' axis of the RAS. Drug therapies targeting the RAS by inhibiting Ang II formation (ACE inhibitors) or binding to its receptor (angiotensin receptor blockers) are now in widespread clinical use and have been shown to reduce tissue injury and fibrosis in cardiac and renal disease independently of their effects on blood pressure. In 2000, two groups using different methodologies identified a homolog of ACE, called ACE2, which cleaves Ang II to form the biologically active heptapeptide, Ang-(1-7). Conceptually, ACE2, Ang-(1-7), and its putative receptor, the mas receptor represent an 'alternative' axis of the RAS capable of opposing the often deleterious actions of Ang II. Interestingly, ACE inhibitors and angiotensin receptor blockers increase Ang-(1-7) production and it has been proposed that some of the beneficial effects of these drugs are mediated through upregulation of Ang-(1-7) rather than inhibition of Ang II production or receptor binding. The present review focuses on the novel components and pathways of the RAS with particular reference to their potential contribution towards the pathophysiology of liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.